WO2005115427A1 - Herbal medicine composition for suppression of obesity and preparation method thereof - Google Patents
Herbal medicine composition for suppression of obesity and preparation method thereof Download PDFInfo
- Publication number
- WO2005115427A1 WO2005115427A1 PCT/KR2005/001626 KR2005001626W WO2005115427A1 WO 2005115427 A1 WO2005115427 A1 WO 2005115427A1 KR 2005001626 W KR2005001626 W KR 2005001626W WO 2005115427 A1 WO2005115427 A1 WO 2005115427A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- weight
- parts
- obesity
- feed
- fat
- Prior art date
Links
- 208000008589 Obesity Diseases 0.000 title claims abstract description 80
- 235000020824 obesity Nutrition 0.000 title claims abstract description 76
- 239000000203 mixture Substances 0.000 title claims abstract description 57
- 238000002360 preparation method Methods 0.000 title abstract description 7
- 241000411851 herbal medicine Species 0.000 title description 2
- 230000001629 suppression Effects 0.000 title description 2
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 44
- 244000020518 Carthamus tinctorius Species 0.000 claims abstract description 9
- 235000003255 Carthamus tinctorius Nutrition 0.000 claims abstract description 9
- 244000241872 Lycium chinense Species 0.000 claims abstract description 9
- 244000183685 Citrus aurantium Species 0.000 claims abstract description 8
- 235000007716 Citrus aurantium Nutrition 0.000 claims abstract description 8
- 235000000228 Citrus myrtifolia Nutrition 0.000 claims abstract description 8
- 235000016646 Citrus taiwanica Nutrition 0.000 claims abstract description 8
- 240000002853 Nelumbo nucifera Species 0.000 claims abstract description 8
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims abstract description 8
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims abstract description 8
- 244000197580 Poria cocos Species 0.000 claims abstract description 8
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 8
- 241000405911 Rehmannia glutinosa Species 0.000 claims abstract description 8
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 8
- 210000000582 semen Anatomy 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims description 8
- 239000000706 filtrate Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 4
- 239000012141 concentrate Substances 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 238000003809 water extraction Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 25
- 239000008280 blood Substances 0.000 abstract description 19
- 210000004369 blood Anatomy 0.000 abstract description 19
- 230000037396 body weight Effects 0.000 abstract description 18
- 230000009467 reduction Effects 0.000 abstract description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 6
- 201000010099 disease Diseases 0.000 abstract description 5
- 210000000577 adipose tissue Anatomy 0.000 abstract description 2
- 239000003925 fat Substances 0.000 description 50
- 241000700159 Rattus Species 0.000 description 41
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 16
- 230000001939 inductive effect Effects 0.000 description 15
- 238000012360 testing method Methods 0.000 description 13
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 10
- 238000010586 diagram Methods 0.000 description 10
- 235000009200 high fat diet Nutrition 0.000 description 7
- 108010028554 LDL Cholesterol Proteins 0.000 description 6
- 238000008214 LDL Cholesterol Methods 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 6
- 235000021588 free fatty acids Nutrition 0.000 description 6
- 231100000419 toxicity Toxicity 0.000 description 6
- 208000007536 Thrombosis Diseases 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 229940109239 creatinine Drugs 0.000 description 5
- 235000021050 feed intake Nutrition 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- 230000007056 liver toxicity Effects 0.000 description 5
- 150000003904 phospholipids Chemical class 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 108010082126 Alanine transaminase Proteins 0.000 description 4
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 4
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 231100000304 hepatotoxicity Toxicity 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000004130 lipolysis Effects 0.000 description 4
- 231100000417 nephrotoxicity Toxicity 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 206010028372 Muscular weakness Diseases 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000027939 micturition Effects 0.000 description 3
- 230000036473 myasthenia Effects 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 3
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- 102000003929 Transaminases Human genes 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 229960002464 fluoxetine Drugs 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000000116 mitigating effect Effects 0.000 description 2
- 229960001243 orlistat Drugs 0.000 description 2
- 229940076279 serotonin Drugs 0.000 description 2
- 229960004425 sibutramine Drugs 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000013585 weight reducing agent Substances 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 1
- 206010061619 Deformity Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 102000004286 Hydroxymethylglutaryl CoA Reductases Human genes 0.000 description 1
- 108090000895 Hydroxymethylglutaryl CoA Reductases Proteins 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 206010024264 Lethargy Diseases 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 229940086609 Lipase inhibitor Drugs 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 210000003486 adipose tissue brown Anatomy 0.000 description 1
- 229960003767 alanine Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 239000000883 anti-obesity agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 229940125710 antiobesity agent Drugs 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000010247 heart contraction Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 239000006049 herbal material Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000021332 multicellular organism growth Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 231100001092 no hepatotoxicity Toxicity 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940035613 prozac Drugs 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 239000000021 stimulant Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000476 thermogenic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229940002552 xenical Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/80—Scrophulariaceae (Figwort family)
- A61K36/804—Rehmannia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
- A61K36/8994—Coix (Job's tears)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Definitions
- the present invention relates to a herbal medicinal composition for inhibiting obesity and a preparation method thereof, and more particularly, to a herbal medicinal composition for inhibiting obesity, which comprises Lycium chinensis Miller, steamed rehmannia glutinosa, Cocicis semen, Carthamus tinctorius, Poria cocos, Angelicae gigantis radix, lotus fruit, Dioscoreae rhizoma, and Citrus aurantium, as well as a preparation method thereof.
- a herbal medicinal composition for inhibiting obesity which comprises Lycium chinensis Miller, steamed rehmannia glutinosa, Cocicis semen, Carthamus tinctorius, Poria cocos, Angelicae gigantis radix, lotus fruit, Dioscoreae rhizoma, and Citrus aurantium, as well as a preparation method thereof.
- Obesity refers to a condition where body fat was excessively accumulated in the body. It does not means a condition of excessive bodyweight but rather means a condition where fat was excessively accumulated in the body due to metabolic disorder. Namely, calorie intake exceeds energy required for the body activity and growth so that it is excessively accumulated in fat tissue in the form of neutral fat, thus causing obesity.
- drugs for the treatment of obesity include fat accumulation inhibitors (appetite inhibitors and agents for inhibiting food absorption or fatty acid production) and fat utilization stimulants (thermogenic or lypolytic agents), and agents recently frequently used in the clinical field include fluoxetine, orlistat, sibutramine and the like.
- Fluoxetine (commercially available under the tradename "Prozac") is a selective serotonin reuptake inhibitor used as an antidepressant, and it has only a temporary effect on a reduction in bodyweight and involves side effects, such as enervation, perspiration and lethargy.
- Orlistat (commercially available under the tradename “Xenical") inhibits the activity of lipase in the small intestines to reduce fat absorption by about 30%, but causes fat feces and requires the supplement of fat-soluble vitamin upon long-term administration.
- Sibutramine (commercially available under the tradename “Reductil”) shows the double action of inhibiting the reuptake of serotonin and norepinephrine, but an increase in serotonin activates the sympathetic system to increase exothermic reaction in brown fat tissue and involves side effects, such as blood pressure increase, mouth drying, constipation and insomnia.
- the present invention provides a herbal medicinal composition
- a herbal medicinal composition comprising 12-17 parts by weight of Lycium chinensis Miller, 12-17 parts by weight of steamed rehmannia glutinosa, 10-38 parts by weight of Cocicis semen, 9-14 parts by weight of Carthamus tinctorius, 5-7 parts by weight of Poria cocos, 9-14 parts by weight of Angelicae gigantis radix, 5-7 parts by weight of lotus fruit, 5-7 parts by weight of Dioscoreae rhizoma, and 5-7 parts by weight of Citrus aurantium.
- the present invention provides a method for preparing a herbal medicinal composition for inhibiting obesity, the method comprising the steps of: crushing a herbal mixture comprising Lycium chinensis Miller, steamed rehmannia glutinosa, Cocicis semen, Carthamus tinctorius, Poria cocos, Angelicae gigantis radix, lotus fruit, Dioscoreae rhizoma, and Citrus aurantium extracting the crushed powder with a solvent; filtering the extract to obtain a filtrate; concentrating the filtrate; and freeze-drying the concentrate.
- a herbal mixture comprising Lycium chinensis Miller, steamed rehmannia glutinosa, Cocicis semen, Carthamus tinctorius, Poria cocos, Angelicae gigantis radix, lotus fruit, Dioscoreae rhizoma, and Citrus aurantium extracting the crushed powder with a solvent; filtering the extract to obtain a filtrate;
- the extraction step is preferably performed by a hot- water extraction process at 80-100 °C for 1-3 hours.
- the composition for inhibiting or treating obesity can be provided which reduces blood fat levels without fatal side effects, and thus, is effective in inhibiting or treating over bodyweight, obesity, and various diseases induced by obesity.
- FIG. 1 is a graphic diagram showing the comparison of the cholesterol level of rats ingested with obesity-inhibiting feed with those of rats ingested with normal feed and rats ingested with obesity-inducing high-fat feed.
- FIG. 2 is a graphic diagram showing the comparison of the LDL-cholesterol level of rats ingested with obesity-inhibiting feed with those of rats ingested with normal feed and rats ingested with obesity-inducing high-fat feed.
- FIG. 3 is a graphic diagram showing the comparison of the total lipid level of rats ingested with obesity-inhibiting feed with those of rats ingested with normal feed and rats ingested with obesity-inducing high-fat feed.
- FIG. 14 is a graphic diagram showing the comparison of the cholesterol level of rats ingested with obesity-inhibiting feed with those of rats ingested with normal feed and rats ingested with obesity-inducing high-fat feed.
- FIG. 4 is a graphic diagram showing the comparison of the triglyceride level of rats ingested with obesity-inhibiting feed with those of rats ingested with normal feed and rats ingested with obesity-inducing high-fat feed.
- FIG. 5 is a graphic diagram showing the comparison of the free fatty acid level of rats ingested with obesity-inhibiting feed with those of rats ingested with normal feed and rats ingested with obesity-inducing high-fat feed.
- FIG. 6 is a graphic diagram showing the comparison of the phospholipid level of rats ingested with obesity-inhibiting feed with those of rats ingested with normal feed and rats ingested with obesity-inducing high-fat feed. [17] FIG.
- FIG. 7 is a graphic diagram showing the comparison of the SGOT level of rats ingested with obesity-inhibiting feed with those of rats ingested with normal feed and rats ingested with obesity-inducing high-fat feed.
- FIG. 8 is a graphic diagram showing the comparison of the SGPT level of rats ingested with obesity-inhibiting feed with those of rats ingested with normal feed and rats ingested with obesity-inducing high-fat feed.
- FIG. 9 is a graphic diagram showing the comparison of the creatinine level of rats ingested with obesity-inhibiting feed with those of rats ingested with normal feed and rats ingested with obesity-causing high-fat feed. [20] FIG.
- FIG. 10 is a graphic diagram showing the comparison of the BUN level of rats ingested with obesity-inhibiting feed with those of rats ingested with normal feed and rats ingested with obesity-inducing high-fat feed. [21] Values shown in each of the drawings are expressed as mean+SEM.
- Cocicis semenis low in calorie and has various functions, such as the promotion of urination. Thus, it is used regularly used as diet food for diabetes and has the pharmacological action to reduce appetite.
- Carthamus tinctorius has the effects of mitigating and treating ischemic heart diseases and brain diseases and inhibiting platelet aggregation reaction, thus inhibiting blood thrombosis.
- Poria cocos has pharmacological actions, such as urination, lowering of blood glucose, hemolysis inhibition, increase of heart contraction, and immune enhancement.
- Angelicae gigantis radix has the actions of blood nourishing, removal of ex- travasated blood, and sedation, and has the pharmacological action to activate blood circulation by reducing blood clots in blood.
- the lotus fruit contains a large amount of useful proteins and is used for nutrition strengthening, body weakness, recovery of the body from diarrhea, and the like. In addition, it has the pharmacological actions to reduce the blood fat of obesity rats induced by high-fat diets, and to inhibit platelet aggregation reaction, thus inhibiting blood thrombosis.
- Lycium chinensis Miller has the effects of removing the deposition of cholesterol, decomposing fat accumulated in the liver, and lowering blood glucose level.
- Steamed rehmannia glutinosa has the effects of reducing appetite and inducing lipolysis.
- Dioscoreae rhizoma has the effects of lowering blood glucose level and acting on the digestive system to recover the renal tube from damage and to protect blood vessels from inflammation and the lever from damage.
- Citrus aurantium has the effect of lowering blood pressure.
- steamed rehmannia glutinosa inducing lipolysis in fat cells is used in an amount of 12 parts by weight in the inventive composition, it will be effective in lipolysis, but it is used in an amount of 17 parts by weight, it can result in excessive lipolysis, thus causing an increase in blood fat level, an opposite phenomenon to antiobesity.
- the content of Cocicis semen in the inventive herbal composition should be 10-38 parts by weight, in which case it can provide effective urination while preventing gout and the like, the general side effects of a diuretic.
- Poria cocos is added in an amount of 5-7 parts by weight is similar to the case of Cocicis semen.
- Carthamus tinctorius is preferably used in an amount of 9-14 parts by weight.
- Angelicae gigantis radixis preferably used in an amount of 9-14 parts by weight in the inventive herbal composition, in order to effectively blood circulation disorder and to prevent myasthenia, bleeding and the like, which occur in the existing drugs for inhibiting blood fatness and thrombosis.
- the content of the lotus fruit in the inventive herbal composition is less than 5 parts by weight, it will not be effective in mitigating thrombosis, ateriosclerosis and the like, and if it is used in an amount of more than 7 parts by weight, it can cause myasthenia, bleeding and the like.
- Dioscoreae rhizoma when used in an amount of 5-7 parts by weight in the inventive herbal composition, is effective in recovering the renal tube to remove the inflammation of blood vessels and to inhibit liver damage and prevents immune deterioration.
- Citrus aurantium when used in an amount of 5-7 parts by weight in the inventive herbal composition, is effective in maintaining blood pressure at a suitable level.
- Each of the herbal materials of the inventive herbal medicinal composition was crushed to powder. Then, the crushed powders were mixed with each other at a weight ratio given in Table 1 below, and the mixed powder was placed in a flask containing distilled water and extracted with hot water at 100 °C for 1 hour. Then, the extract was filtered through gauze, and the filtrate was concentrate in reduced pressure and freeze- dried.
- feed was prepared in such a manner that the inventive composition was contained in an amount of 2.2 g per 100 g of the feed.
- Test Example 1 Preparation of high-fat feed and obesity-inducing test using the same
- Purina feed containing 20% of fat was crushed with a grinder, introduced with either a small amount of water or the inventive composition and a small amount of water, and then kneaded into the general shape of feed. Next, the kneaded material was dried in a hood at room temperature for 24 hours.
- the rats divided into the three groups were fasted for 24 hours before administration with the feed. Then, the rats were administered with the normal feed, the obesity-inducing high-fat feed and the obesity-inhibiting feed for 6 weeks. The body weight of the rats was measured at one- week intervals. The results are shown in Table 2. As could be seen in Table 2, the high-fat feed group showed a statistically significant increase in body weight for 1-6 weeks as compared to the normal feed group. On the contrary, the rats administered with the obesity inhibiting feed showed a significant inhibition in the increase of body weight induced by the high-fat diet.
- the weight of renal fat, another index of obesity was measured on each of the groups, and the results are shown in Table 2.
- Table 2 the high-fat feed group showed an increase of 26% in fat level as compared to the normal feed, but the obesity inhibiting feed group showed a reduction of 28% in the increased fat level.
- Test Example 2 Obesity inhibiting test using inventive composition in obesity- induced animal models
- Rats were divided into three groups as described in Test Example 1 and administered with different feeds for 6 weeks. Then, blood was collected from the heart of each of the rats. Serum was separated from the collected blood and measured for cholesterol, LDL-cholesterol, triglyceride, free fatty acid, phospholipid and total lipid levels, which are indicative of obesity. As a result, as can be seen in FIGS. 1 to 3, the high-fat feed group showed a statistically significant increase in cholesterol as compared to the normal feed group, LDL-cholesterol and total lipid levels, indicating that obesity was induced. On the contrary, the obesity-inhibiting feed group administered with the inventive composition showed a significant reduction in these increased levels.
- the obesity-inhibiting feed group showed reductions of 22%, 27% and 10% in the increased triglyceride, free fatty acid and phospholipid levels, respectively, as compared to the high-fat feed group. This indicates that obesity was induced by the high-fat feed, thus increasing cholesterol, LDL-cholesterol, triglyceride, free fatty acid, phospholipid and total lipid levels, and the inventive composition reduced such levels.
- the inventive composition can be used as agents for inhibiting obesity and treating obesity-related diseases, such as hyper- lipidemia, ateriosclerosisand the like.
- the inventive composition reduced free fatty acid, phospholipid and neutral fat to a significant extent.
- Such reductions in total cholesterol and LDL- cholesterol levels are supposed to occur because the inventive composition either inhibits the HMG-CoA reductase, the most important regulatory enzymefor the biosynthesis of cholesterol, or promotes the effective distribution and migration of LDL-cholesterol into various tissues.
- the reductions in free fatty acid, phopholipid, neutral fat and total lipid levels by the inventive composition are because the inventive composition inhibits the absorption of fats ingested as food in the intestinal tracts, like a lipase inhibitor decomposing fats in the stomach and intestinal tracts into simple forms so as to make fat absorption easy.
- Test Example 3 Tests of inventive composition on liver toxicity and kidney toxicity
- L-alanine aminotransferase (ALT or SGPT) and L-aspartate aminotransferase (AST or SGOT)are known to be indicative of liver toxicity, and their significant increase means the deterioration of liver function and toxicity and can be frequently seen in obesity persons who mostly have fatty liver. Therefore, the inhibition of activity of such enzymes can be considered to be indicative of obesity inhibition and is important in determining the absence of toxicity.
- FIG. 8 the significance of SGPT was not found in the normal feed group, the high-fat feed group and the obesity-inhibiting feed group. This suggests that the high-fat diet containing the inventive composition does not cause an increase in the activities of these enzymes, and the inventive composition does not show liver toxicity harmful to the human body.
- the feed containing the inventive composition significantly reduced the activity of SGOT. This indicates that the inventive composition has not only no liver toxicity but also the effect of protecting the liver.
- Test Example 4 Toxicity test of inventive composition on reduction of body weight
- Test Example 5 Examination of difference in feed intake between high-fat feed group and obesity-inhibiting feed group
- the inventive composition was measured for the following side effects: body weight reduction, which is the general toxicity of prior obesity-treating agents; BUN and creatinine levels indicative of kidney toxicity; and blood SGOT and SGPT levels indicative of liver toxicity. The measurement results showed that the inventive composition had no toxicity. In addition, it was found by the feed intake measurement that the obesity-inhibiting effect of the inventive composition is not a result of a nonpharmacological factor caused by taste or odor, i.e., food rejection.
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a herbal medicinal composition for inhibiting obesity and a preparation method thereof. The herbal composition comprises 12~17 parts by weight of Lycium chinensis Miller, 12~17 parts by weight of steamed rehmannia glutinosa, 10~38 parts by weight of Coicis semen, 9~14 parts by weight of Carthamus tinctorius, 5~7 parts by weight of Poria cocos, 9~14 parts by weight of Angelicae gigantis radix, 5~7 parts by weight of lotus fruit, 5~7 parts by weight of Dioscoreae rhizoma, and 5~7 parts by weight of Citrus aurantium. The composition allows the reduction of body fat or blood fat without causing fatal side effects, and thus, is effective in inhibiting or treating over body weight, obesity and various diseases induced by obesity.
Description
Description HERBAL MEDICINE COMPOSITION FOR SUPPRESSION OF OBESITY AND PREPARATION METHOD THEREOF Technical Field
[1] The present invention relates to a herbal medicinal composition for inhibiting obesity and a preparation method thereof, and more particularly, to a herbal medicinal composition for inhibiting obesity, which comprises Lycium chinensis Miller, steamed rehmannia glutinosa, Cocicis semen, Carthamus tinctorius, Poria cocos, Angelicae gigantis radix, lotus fruit, Dioscoreae rhizoma, and Citrus aurantium, as well as a preparation method thereof. Background Art
[2] Obesity refers to a condition where body fat was excessively accumulated in the body. It does not means a condition of excessive bodyweight but rather means a condition where fat was excessively accumulated in the body due to metabolic disorder. Namely, calorie intake exceeds energy required for the body activity and growth so that it is excessively accumulated in fat tissue in the form of neutral fat, thus causing obesity.
[3] Even by itself, obesity causes so-called "5D" indicating that obesity causes not only disfigurement, discomfort and disability, but also diseases, such as cardiovascular diseases, including hyperlipidemia, hypercholesterolemia, hypertension, ate- riosclerosis, and myocardial infarction, renal disease, type II insulin-independent diabetes, and pulmonary disease, and these diseases lead to death. In highly developed countries, 30% of total adults have obesity, and particularly, the mortality of men with obesity is about 12 times higher in a young age group (25-34 years old), and the main cause of the death was found to be cardiovascular diseases.
[4] In order to treat this obesity, studies are currently performed on diet therapy, exercise therapy, behavior modification therapy, surgical therapy, drug therapy and the like. Meanwhile, drugs for the treatment of obesity include fat accumulation inhibitors (appetite inhibitors and agents for inhibiting food absorption or fatty acid production) and fat utilization stimulants (thermogenic or lypolytic agents), and agents recently frequently used in the clinical field include fluoxetine, orlistat, sibutramine and the like. Fluoxetine (commercially available under the tradename "Prozac") is a selective serotonin reuptake inhibitor used as an antidepressant, and it has only a temporary effect on a reduction in bodyweight and involves side effects, such as enervation, perspiration and lethargy. Orlistat (commercially available under the tradename "Xenical") inhibits the activity of lipase in the small intestines to reduce fat absorption
by about 30%, but causes fat feces and requires the supplement of fat-soluble vitamin upon long-term administration. Sibutramine (commercially available under the tradename "Reductil") shows the double action of inhibiting the reuptake of serotonin and norepinephrine, but an increase in serotonin activates the sympathetic system to increase exothermic reaction in brown fat tissue and involves side effects, such as blood pressure increase, mouth drying, constipation and insomnia.
[5] As described above, obesity is the main factor of mortally threatening life, but there is still no therapeutic agent of effectively treating such obesity without involving the above-described side effects. Accordingly, there is an urgent need for the development of a safe and effective antiobesity agent. Disclosure of Invention Technical Problem
[6] It is an object of the present invention to provide a herbal medicinal composition which is excellent in inhibitory and therapeutic effects against obesity and symptoms involved in obesity and has no side effects, as well as a preparation method thereof. Technical Solution
[7] To achieve the above object, in one aspect, the present invention provides a herbal medicinal composition comprising 12-17 parts by weight of Lycium chinensis Miller, 12-17 parts by weight of steamed rehmannia glutinosa, 10-38 parts by weight of Cocicis semen, 9-14 parts by weight of Carthamus tinctorius, 5-7 parts by weight of Poria cocos, 9-14 parts by weight of Angelicae gigantis radix, 5-7 parts by weight of lotus fruit, 5-7 parts by weight of Dioscoreae rhizoma, and 5-7 parts by weight of Citrus aurantium.
[8] In another aspect, the present invention provides a method for preparing a herbal medicinal composition for inhibiting obesity, the method comprising the steps of: crushing a herbal mixture comprising Lycium chinensis Miller, steamed rehmannia glutinosa, Cocicis semen, Carthamus tinctorius, Poria cocos, Angelicae gigantis radix, lotus fruit, Dioscoreae rhizoma, and Citrus aurantium extracting the crushed powder with a solvent; filtering the extract to obtain a filtrate; concentrating the filtrate; and freeze-drying the concentrate.
[9] In the inventive method, the extraction step is preferably performed by a hot- water extraction process at 80-100 °C for 1-3 hours. Advantageous Effects
[10] As described above, according to the present invention, the composition for inhibiting or treating obesity can be provided which reduces blood fat levels without fatal side effects, and thus, is effective in inhibiting or treating over bodyweight, obesity, and various diseases induced by obesity.
Brief Description of the Drawings
[11] FIG. 1 is a graphic diagram showing the comparison of the cholesterol level of rats ingested with obesity-inhibiting feed with those of rats ingested with normal feed and rats ingested with obesity-inducing high-fat feed. [12] FIG. 2 is a graphic diagram showing the comparison of the LDL-cholesterol level of rats ingested with obesity-inhibiting feed with those of rats ingested with normal feed and rats ingested with obesity-inducing high-fat feed. [13] FIG. 3 is a graphic diagram showing the comparison of the total lipid level of rats ingested with obesity-inhibiting feed with those of rats ingested with normal feed and rats ingested with obesity-inducing high-fat feed. [14] FIG. 4 is a graphic diagram showing the comparison of the triglyceride level of rats ingested with obesity-inhibiting feed with those of rats ingested with normal feed and rats ingested with obesity-inducing high-fat feed. [15] FIG. 5 is a graphic diagram showing the comparison of the free fatty acid level of rats ingested with obesity-inhibiting feed with those of rats ingested with normal feed and rats ingested with obesity-inducing high-fat feed. [16] FIG. 6 is a graphic diagram showing the comparison of the phospholipid level of rats ingested with obesity-inhibiting feed with those of rats ingested with normal feed and rats ingested with obesity-inducing high-fat feed. [17] FIG. 7 is a graphic diagram showing the comparison of the SGOT level of rats ingested with obesity-inhibiting feed with those of rats ingested with normal feed and rats ingested with obesity-inducing high-fat feed. [18] FIG. 8 is a graphic diagram showing the comparison of the SGPT level of rats ingested with obesity-inhibiting feed with those of rats ingested with normal feed and rats ingested with obesity-inducing high-fat feed. [19] FIG. 9 is a graphic diagram showing the comparison of the creatinine level of rats ingested with obesity-inhibiting feed with those of rats ingested with normal feed and rats ingested with obesity-causing high-fat feed. [20] FIG. 10 is a graphic diagram showing the comparison of the BUN level of rats ingested with obesity-inhibiting feed with those of rats ingested with normal feed and rats ingested with obesity-inducing high-fat feed. [21] Values shown in each of the drawings are expressed as mean+SEM.
[22] * p<0.05, ** p<0.01, *** p<0.005, **** p<0.001: showed a statistically significant difference when compared with the high-fat feed group (C)and the normal feed group (N). Best Mode for Carrying Out the Invention [23] Hereinafter, the present invention will be described in detail.
[24] Cocicis semenis low in calorie and has various functions, such as the promotion of urination. Thus, it is used regularly used as diet food for diabetes and has the pharmacological action to reduce appetite.
[25] Carthamus tinctorius has the effects of mitigating and treating ischemic heart diseases and brain diseases and inhibiting platelet aggregation reaction, thus inhibiting blood thrombosis.
[26] Poria cocos has pharmacological actions, such as urination, lowering of blood glucose, hemolysis inhibition, increase of heart contraction, and immune enhancement.
[27] Angelicae gigantis radix has the actions of blood nourishing, removal of ex- travasated blood, and sedation, and has the pharmacological action to activate blood circulation by reducing blood clots in blood.
[28] The lotus fruit contains a large amount of useful proteins and is used for nutrition strengthening, body weakness, recovery of the body from diarrhea, and the like. In addition, it has the pharmacological actions to reduce the blood fat of obesity rats induced by high-fat diets, and to inhibit platelet aggregation reaction, thus inhibiting blood thrombosis.
[29] Lycium chinensis Miller has the effects of removing the deposition of cholesterol, decomposing fat accumulated in the liver, and lowering blood glucose level. Steamed rehmannia glutinosa has the effects of reducing appetite and inducing lipolysis.
[30] Dioscoreae rhizoma has the effects of lowering blood glucose level and acting on the digestive system to recover the renal tube from damage and to protect blood vessels from inflammation and the lever from damage. In addition, Citrus aurantium has the effect of lowering blood pressure.
[31] Meanwhile, if the content of Lycium chinensis Miller in the inventive composition is less than 12 parts by weight, it cannot effectively remove blood fat, and if the content of Lycium chinensis Miller is more than 17 parts by weight, it can result in a rapid reduction in blood fat levels, particularly blood cholesterol levels, thus causing side effects, such as myasthenia.
[32] If steamed rehmannia glutinosa inducing lipolysis in fat cells is used in an amount of 12 parts by weight in the inventive composition, it will be effective in lipolysis, but it is used in an amount of 17 parts by weight, it can result in excessive lipolysis, thus causing an increase in blood fat level, an opposite phenomenon to antiobesity.
[33] The content of Cocicis semen in the inventive herbal composition should be 10-38 parts by weight, in which case it can provide effective urination while preventing gout and the like, the general side effects of a diuretic. The reason why Poria cocos is added in an amount of 5-7 parts by weight is similar to the case of Cocicis semen.
[34] If the content of Carthamus tinctorius in the inventive herbal composition is less than 9 parts by weight, it will not be effective in treating cardiovascular diseases
induced by obesity, and if it is more than 14 parts by weight, it can show a side effect of bleeding. For this reason, Carthamus tinctorius is preferably used in an amount of 9-14 parts by weight.
[35] Angelicae gigantis radixis preferably used in an amount of 9-14 parts by weight in the inventive herbal composition, in order to effectively blood circulation disorder and to prevent myasthenia, bleeding and the like, which occur in the existing drugs for inhibiting blood fatness and thrombosis.
[36] If the content of the lotus fruit in the inventive herbal composition is less than 5 parts by weight, it will not be effective in mitigating thrombosis, ateriosclerosis and the like, and if it is used in an amount of more than 7 parts by weight, it can cause myasthenia, bleeding and the like.
[37] Dioscoreae rhizoma, when used in an amount of 5-7 parts by weight in the inventive herbal composition, is effective in recovering the renal tube to remove the inflammation of blood vessels and to inhibit liver damage and prevents immune deterioration.
[38] Citrus aurantium, when used in an amount of 5-7 parts by weight in the inventive herbal composition, is effective in maintaining blood pressure at a suitable level. Mode for the Invention
[39] Hereinafter, the present invention will be described in detail by examples. It is to be understood, however, that these examples are for illustrative purpose only and not construed to limit the scope of the present invention.
[40] Example
[41] Each of the herbal materials of the inventive herbal medicinal composition was crushed to powder. Then, the crushed powders were mixed with each other at a weight ratio given in Table 1 below, and the mixed powder was placed in a flask containing distilled water and extracted with hot water at 100 °C for 1 hour. Then, the extract was filtered through gauze, and the filtrate was concentrate in reduced pressure and freeze- dried.
[42] Meanwhile, for use in animal tests to examine whether the inventive herbal composition has the effect of inhibiting obesity, feed was prepared in such a manner that the inventive composition was contained in an amount of 2.2 g per 100 g of the feed.
[43] Table 1
[44] [45] Test Example 1 : Preparation of high-fat feed and obesity-inducing test using the same
[46] 85~95-day-old male Sprague-Dawley rats weighing 19~250g were accommodated in a breeding chamber with constantly maintained temperature and humidity and no pathogenic bacteria for 2 weeks while permitting free access to water and feed. Then, the rats were divided into the following three groups each consisting of 8 animals:
[47] (1) Normal feed group: general rat feed (Samtako Co.; 5% fat content; indicated by "N"). [48] (2) Obesity-inducing high-fat feed group: feed with a total fat content of 20% (Purina Korea Inc.; 20% tallow fat; indicated by "C"). [49] (3) Obesity-inhibiting feed group: obesity-inducing high-fat feed group + the inventive composition (indicated by "C + P"). [50] The components and contents thereof in the inventive composition, and the contents of the components in the prepared feed, are shown in Table 1 above. The two feeds except for normal feed group were prepared in the following manner. Purina feed containing 20% of fat was crushed with a grinder, introduced with either a small amount of water or the inventive composition and a small amount of water, and then kneaded into the general shape of feed. Next, the kneaded material was dried in a hood at room temperature for 24 hours.
[51] The rats divided into the three groups were fasted for 24 hours before administration with the feed. Then, the rats were administered with the normal feed, the obesity-inducing high-fat feed and the obesity-inhibiting feed for 6 weeks. The body weight of the rats was measured at one- week intervals. The results are shown in Table 2. As could be seen in Table 2, the high-fat feed group showed a statistically
significant increase in body weight for 1-6 weeks as compared to the normal feed group. On the contrary, the rats administered with the obesity inhibiting feed showed a significant inhibition in the increase of body weight induced by the high-fat diet.
[52] Also, the weight of renal fat, another index of obesity, was measured on each of the groups, and the results are shown in Table 2. As can be seen in Table 2, the high-fat feed group showed an increase of 26% in fat level as compared to the normal feed, but the obesity inhibiting feed group showed a reduction of 28% in the increased fat level. These results suggest that the high-fat diet induced increases in body weight and fat level (i.e., obesity), and the inventive composition has the effect of inhibiting obesity induced by the high-fat diet.
[53] Table 2
[54] [55] The values in Table 2 are expressed as mean+SEM. [56] ap<0.05, p<0.01, °p<0.005, p<0.001: showed a statistically significant difference when compared to the high-fat feed group.
[57] Test Example 2: Obesity inhibiting test using inventive composition in obesity- induced animal models
[58] Rats were divided into three groups as described in Test Example 1 and administered with different feeds for 6 weeks. Then, blood was collected from the heart of each of the rats. Serum was separated from the collected blood and measured for cholesterol, LDL-cholesterol, triglyceride, free fatty acid, phospholipid and total lipid levels, which are indicative of obesity. As a result, as can be seen in FIGS. 1 to 3, the
high-fat feed group showed a statistically significant increase in cholesterol as compared to the normal feed group, LDL-cholesterol and total lipid levels, indicating that obesity was induced. On the contrary, the obesity-inhibiting feed group administered with the inventive composition showed a significant reduction in these increased levels.
[59] Also, as can be seen in FIGS. 4 to 6, the obesity-inhibiting feed group showed reductions of 22%, 27% and 10% in the increased triglyceride, free fatty acid and phospholipid levels, respectively, as compared to the high-fat feed group. This indicates that obesity was induced by the high-fat feed, thus increasing cholesterol, LDL-cholesterol, triglyceride, free fatty acid, phospholipid and total lipid levels, and the inventive composition reduced such levels.
[60] As can be seen in Test Examples above, the inventive composition can be used as agents for inhibiting obesity and treating obesity-related diseases, such as hyper- lipidemia, ateriosclerosisand the like.
[61] Moreover, the inventive composition reduced free fatty acid, phospholipid and neutral fat to a significant extent. Such reductions in total cholesterol and LDL- cholesterol levels are supposed to occur because the inventive composition either inhibits the HMG-CoA reductase, the most important regulatory enzymefor the biosynthesis of cholesterol, or promotes the effective distribution and migration of LDL-cholesterol into various tissues. Furthermore, the reductions in free fatty acid, phopholipid, neutral fat and total lipid levels by the inventive composition are because the inventive composition inhibits the absorption of fats ingested as food in the intestinal tracts, like a lipase inhibitor decomposing fats in the stomach and intestinal tracts into simple forms so as to make fat absorption easy.
[62] Test Example 3: Tests of inventive composition on liver toxicity and kidney toxicity
[63] L-alanine aminotransferase (ALT or SGPT) and L-aspartate aminotransferase (AST or SGOT)are known to be indicative of liver toxicity, and their significant increase means the deterioration of liver function and toxicity and can be frequently seen in obesity persons who mostly have fatty liver. Therefore, the inhibition of activity of such enzymes can be considered to be indicative of obesity inhibition and is important in determining the absence of toxicity. As shown in FIG. 8, the significance of SGPT was not found in the normal feed group, the high-fat feed group and the obesity-inhibiting feed group. This suggests that the high-fat diet containing the inventive composition does not cause an increase in the activities of these enzymes, and the inventive composition does not show liver toxicity harmful to the human body. On the other hand, as could be seen in FIG. 7, the feed containing the inventive composition significantly reduced the activity of SGOT. This indicates that the
inventive composition has not only no liver toxicity but also the effect of protecting the liver.
[64] Meanwhile, increases in creatinine and BUN have been indicative of kidney damage and toxicity. As can be seen in FIG. 9, the significance of creatinine was not found in all the normal feed group, the high-fat feed group and the obesity-inhibiting feed group. This suggests that the high-fat feed containing the inventive composition does not cause an increase in creatinine level, and does not show kidney toxicity. Meanwhile, as shown in FIG. 10, BUN was significantly lower in the obesity- inhibiting feed group than the normal feed group. This suggests that the high-fat diet containing the inventive composition does not cause an increase in BUN level, and shows no kidney toxicity.
[65] Test Example 4: Toxicity test of inventive composition on reduction of body weight
[66] In order to examine whether the inventive composition shows toxicity causing a reduction in body weight even when a normal diet is made, feed having the inventive composition added to the normal feed was prepared in the same manner as in Example and administered to rats for 6 weeks. The body weight of the groups administered with the prepared feed was compared with the body weight of the normal feed group, and the results are shown in Table 3 below. As can be seen in Table 3, although the group administered with the inventive composition-containing feed showed a reduction in body weight after one week (this is perhaps thought to be caused by adaptation to drugs), it showed no change in body weight after that. This suggests that the inventive composition does not show the side effect or toxicity of body weight reduction in normal persons and is effective only in persons with obesity caused by high-fat diets.
[67] Table 3
[69] The values in Table 3 are expressed as mean+SEM. [70] ap<0.05: showed a statistically significant difference when compared to the normal feed group.
[71] Test Example 5: Examination of difference in feed intake between high-fat feed group and obesity-inhibiting feed group
[72] In order to examine whether a reduction in the body weight of an obesity-inhibiting feed group is caused by the substantial effect of the inventive composition on the reduction of body weight or caused by a reduction in feed intake due to the odor or taste of the inventive composition, rats were divided into a high-fat feed group and an obesity-inhibiting feed group and examined for feed intake during 5 days before the end of the test. As a result, as can be seen in Table 4, there was no difference in feed intake between the two groups, indicating that the obesity-inhibiting effect of the inventive composition is a result of the medicinal effect of the inventive composition.
[73] Table 4
[74] [75] The values in Table 4 are expressed as mean+SEM. [76] In the above Test Examples of the present invention, the inventive composition was measured for the following side effects: body weight reduction, which is the general toxicity of prior obesity-treating agents; BUN and creatinine levels indicative of kidney toxicity; and blood SGOT and SGPT levels indicative of liver toxicity. The measurement results showed that the inventive composition had no toxicity. In addition, it was found by the feed intake measurement that the obesity-inhibiting effect of the inventive composition is not a result of a nonpharmacological factor caused by taste or odor, i.e., food rejection.
Claims
[1] A herbal medicinal composition for inhibiting obesity, comprising 12-17 parts by weight of Lycium chinensis Miller, 12-17 parts by weight of steamed rehmannia glutinosa, 10-38 parts by weight of Cocicis semen, 9-14 parts by weight of Carthamus tinctorius, 5-7 parts by weight of Poria cocos, 9-14 parts by weight of Angelicae gigantis radix, 5-7 parts by weight of lotus fruit, 5-7 parts by weight of Dioscoreae rhizoma, and 5-7 parts by weight of Citrus aurantium.
[2] A method for preparing an herbal medicinal composition for inhibiting obesity, the method comprising the steps of: crushing a herbal mixture comprising Lycium chinensis Miller, steamed rehmannia glutinosa, Cocicis semen, Carthamus tinctorius, Poria cocos, Angelicae gigantis radix, lotus fruit, Dioscoreae rhizoma, and Citrus aurantium; extracting the crushed powder with a solvent; filtering the extract to obtain a filtrate; concentrating the filtrate; and freeze-drying the concentrate.
[3] The method of Claim 2, wherein the extraction step is performed by a hot-water extraction process at 80-100 °C for 1-3 hours.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2004-0039234 | 2004-05-31 | ||
| KR1020040039234A KR100641807B1 (en) | 2004-05-31 | 2004-05-31 | Mixture for preventing obesity and Method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2005115427A1 true WO2005115427A1 (en) | 2005-12-08 |
Family
ID=35450657
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/KR2005/001626 WO2005115427A1 (en) | 2004-05-31 | 2005-05-31 | Herbal medicine composition for suppression of obesity and preparation method thereof |
Country Status (2)
| Country | Link |
|---|---|
| KR (1) | KR100641807B1 (en) |
| WO (1) | WO2005115427A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103239551A (en) * | 2013-01-16 | 2013-08-14 | 济南康众医药科技开发有限公司 | Freeze-dried radix rehmanniae for preventing and curing obesity |
| CN110250526A (en) * | 2019-07-05 | 2019-09-20 | 青海瑞湖生物资源开发有限公司 | A kind of health food and preparation method thereof with auxiliary lipid-lowering function |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103298477B (en) * | 2010-09-10 | 2015-09-02 | 韩国食品研究院 | Comprise Lignum Cudraniae tricuspidatae and Semen Coicis for suppressing fat or falling hypoglycemic composition and use thereof |
| KR101330687B1 (en) * | 2011-09-21 | 2013-11-18 | 경희대학교 산학협력단 | Composition for treating and preventing obesity containing oriental herbal extracts |
| KR101412221B1 (en) * | 2012-08-14 | 2014-06-27 | (주)바이오뉴트리젠 | Composition of antiobesity containing Lycium chinensis leaf extract powder and betaine as effective ingredients |
| CN106562988B (en) * | 2016-11-11 | 2020-02-18 | 华南理工大学 | Application of substituted calyx polysaccharide in preparation of weight-reducing medicine |
| WO2019083225A1 (en) * | 2017-10-23 | 2019-05-02 | 이영구 | Traditional chinese medicinal diet management system and method therefor |
| KR102198802B1 (en) * | 2018-12-07 | 2021-01-06 | 주식회사 우리엘바이오 | Method for manufacturing antiobesic bio oriental medicine mixed extract and antiobesic bio oriental medicine mixed extract produded by the same |
| CN111436604A (en) * | 2020-05-29 | 2020-07-24 | 山西振东五和健康科技股份有限公司 | Composition and product for strengthening heart and preventing cardiovascular diseases and preparation method thereof |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100232671B1 (en) * | 1997-07-25 | 2000-02-01 | 김이현 | Process for preparing the composition for treating gyncological disease and women's obesity |
| WO2000030603A1 (en) * | 1998-11-23 | 2000-06-02 | Sederma | Slimming compositions containing a dioscorea opposita extract |
| KR100302024B1 (en) * | 1998-12-04 | 2001-10-29 | 마대규 | Extract of safflower seed for decreasing blood cholesterol level and method for preparation of the same |
| JP2002138045A (en) * | 2000-10-30 | 2002-05-14 | Ichimaru Pharcos Co Ltd | Inhibitor for inhibiting differentiation induction of pre- adipocyte |
| JP2002275078A (en) * | 2001-01-11 | 2002-09-25 | Kanebo Ltd | Lipolysis promoter |
| JP2002356434A (en) * | 2001-03-27 | 2002-12-13 | Nicca Chemical Co Ltd | Lipase activity activating agent, skin care preparation for slimming and bathing agent for slimming |
| KR20020095512A (en) * | 2001-06-14 | 2002-12-27 | 한국 한의학 연구원 | Compositions containing Rehmannia glutinosa extracts for prevention of obesity |
| JP2003113100A (en) * | 2001-10-01 | 2003-04-18 | Pola Chem Ind Inc | Calorigenic protein-expressing promoter and composition containing the same |
| KR20030055127A (en) * | 2001-12-24 | 2003-07-02 | 주식회사 닥터즈메디코아 | Composition for anti-hyperlipidemia |
| KR20030075067A (en) * | 2002-03-15 | 2003-09-22 | 조명하 | Extraction method for product of obese treatment with dried orange peel compound |
-
2004
- 2004-05-31 KR KR1020040039234A patent/KR100641807B1/en not_active IP Right Cessation
-
2005
- 2005-05-31 WO PCT/KR2005/001626 patent/WO2005115427A1/en active Application Filing
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100232671B1 (en) * | 1997-07-25 | 2000-02-01 | 김이현 | Process for preparing the composition for treating gyncological disease and women's obesity |
| WO2000030603A1 (en) * | 1998-11-23 | 2000-06-02 | Sederma | Slimming compositions containing a dioscorea opposita extract |
| KR100302024B1 (en) * | 1998-12-04 | 2001-10-29 | 마대규 | Extract of safflower seed for decreasing blood cholesterol level and method for preparation of the same |
| JP2002138045A (en) * | 2000-10-30 | 2002-05-14 | Ichimaru Pharcos Co Ltd | Inhibitor for inhibiting differentiation induction of pre- adipocyte |
| JP2002275078A (en) * | 2001-01-11 | 2002-09-25 | Kanebo Ltd | Lipolysis promoter |
| JP2002356434A (en) * | 2001-03-27 | 2002-12-13 | Nicca Chemical Co Ltd | Lipase activity activating agent, skin care preparation for slimming and bathing agent for slimming |
| KR20020095512A (en) * | 2001-06-14 | 2002-12-27 | 한국 한의학 연구원 | Compositions containing Rehmannia glutinosa extracts for prevention of obesity |
| JP2003113100A (en) * | 2001-10-01 | 2003-04-18 | Pola Chem Ind Inc | Calorigenic protein-expressing promoter and composition containing the same |
| KR20030055127A (en) * | 2001-12-24 | 2003-07-02 | 주식회사 닥터즈메디코아 | Composition for anti-hyperlipidemia |
| KR20030075067A (en) * | 2002-03-15 | 2003-09-22 | 조명하 | Extraction method for product of obese treatment with dried orange peel compound |
Non-Patent Citations (4)
| Title |
|---|
| KWON C.-S. ET AL: "Anti-obesity effect of Dioscorea nipponica Makino with lipase-inhibitory activity in rodents", BIOSCI. BIOTECHNOL. BIOCHEM., vol. 67, no. 7, 2003, pages 1451 - 1456, XP009083433, DOI: doi:10.1271/bbb.67.1451 * |
| MORO C.O. ET AL: "Obesity and medicinal plants", FITOTERAPIA, vol. 71, no. 1, 2000, pages S73 - S82 * |
| PREUSS H.G. ET AL: "Citrus aurantium as a thermogenic, weight-reduction replacement for ephedra: an overview", J. MED., vol. 33, no. 1-4, 2002, pages 247 - 264, XP009052055 * |
| SATO M. ET AL: "Dehydrotetrametenolic acid induces preadipocyte differentition and sensitizes animal models of noninsulin-dependent diabetes mellitus to insulin", BIOL. PHARM. BULL., vol. 25, no. 1, 2002, pages 81 - 86 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103239551A (en) * | 2013-01-16 | 2013-08-14 | 济南康众医药科技开发有限公司 | Freeze-dried radix rehmanniae for preventing and curing obesity |
| CN110250526A (en) * | 2019-07-05 | 2019-09-20 | 青海瑞湖生物资源开发有限公司 | A kind of health food and preparation method thereof with auxiliary lipid-lowering function |
Also Published As
| Publication number | Publication date |
|---|---|
| KR100641807B1 (en) | 2006-11-02 |
| KR20050114040A (en) | 2005-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6541046B2 (en) | Herbal composition and method for controlling body weight and composition | |
| WO2005115427A1 (en) | Herbal medicine composition for suppression of obesity and preparation method thereof | |
| CN106176918A (en) | A kind of Hyperglycemic health care compositions comprising leaf of Cyclocarya paliurus Iljinskaja and Radix Puerariae | |
| CN103230486B (en) | Traditional Chinese medicine composition, preparation method thereof, and application thereof in preparing medicines used for treating fatty liver | |
| EP1583547B1 (en) | Anti-obesity ingredients from medicinal plants and their composition | |
| CN107412713A (en) | Treat Chinese patent drug, dietetic food and the preparation method of autoimmune and immune related diseases | |
| TW201006389A (en) | Formulations, methods and its use for reducing abdominal fat and waist circumference | |
| CN108498568A (en) | Chinese patent drug, medical food and the preparation method of autoimmune and immune related diseases are treated with Goat Placenta or embryo | |
| JP7340113B2 (en) | Chinese herbal composition and its production method and use | |
| US20040071799A1 (en) | Herbal compositions and methods for effecting weight loss in humans | |
| KR20190111726A (en) | A composition for preventing or treating obesity comprising natural mixture extracts | |
| CN109908202A (en) | A kind of pharmaceutical composition and preparation method thereof for treating hyperuricemia | |
| KR100573592B1 (en) | Imperatae rhizoma Extract for Treatment and Prevention of Obesity | |
| CN102579713B (en) | Traditional Chinese medicine for treating children obesity and preparation method | |
| CN114533835B (en) | A Chinese medicinal composition with effects of removing pathogenic wind and dampness, and its preparation method | |
| CN109303790B (en) | Medical application of caper or caper extract | |
| JP2003226650A (en) | Medicinal composition | |
| KR100573590B1 (en) | New Herbal Composition for Treatment and Prevention of Obesity | |
| CN111298061B (en) | Traditional Chinese medicine composition for clearing heat and detoxicating, removing stasis and resolving masses and preparation method thereof | |
| KR100573591B1 (en) | Liriopsis tuber Extract for Treatment and Prevention of Obesity | |
| HAJI et al. | EFFECT OF GARLIC OIL ON SOME BIOCHEMICAL PARAMETERS IN RATS EXPOSED TO HYDROGEN PEROXIDE | |
| CN106902295B (en) | Toxicity-reducing and efficacy-enhancing traditional Chinese medicine tablet for treating gout with syndrome of wind-damp-heat | |
| JP2011184360A (en) | Extract of sasa veitchii f. tyugokensis, method for producing the same and use thereof | |
| CN102048974B (en) | Application of bagasse for preparing medicine for preventing and treating chronic obstructive pulmonary diseases | |
| CN111281939A (en) | Composition for nourishing stomach, protecting liver and dispelling effects of alcohol and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
| 122 | Ep: pct application non-entry in european phase |